XML 51 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies - Narrative (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 23, 2019
shares
Dec. 31, 2020
USD ($)
unit
Dec. 31, 2020
USD ($)
segment
Dec. 31, 2019
USD ($)
shares
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2016
USD ($)
New Accounting Pronouncement, Early Adoption [Line Items]                  
Restricted cash   $ 100 $ 100 $ 100          
Contract with customer, timing of performance obligation and payment     Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing            
Joint venture, quarterly promotion fee   $ 300 $ 300            
Joint venture quarterly promotion fee cap   5.00% 5.00%       5.00%    
Joint venture, number of units prescribed quarterly | unit   28,750              
Revenue     $ 41,975 40,387          
Advertising Expense     $ 1,300 $ 1,600          
Dividend yield     0.00%            
Number of operating segments | segment     1            
Common Stock                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Stock issued upon conversion of redeemable convertible preferred shares (in shares) | shares       7,816,643          
Common Stock | IPO                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Stock issued upon conversion of redeemable convertible preferred shares (in shares) | shares 7,816,643                
Forecast                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Joint venture quarterly promotion fee cap         10.00% 10.00%      
Minimum                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Property, plant and equipment, useful life     3 years            
Joint venture, quarterly promotion fee per prescription               $ 750  
Joint venture, quarterly promotion fee   $ 300 $ 300       $ 300    
Minimum | Forecast                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Joint venture, quarterly promotion fee per prescription         $ 500 $ 500      
Joint venture, quarterly promotion fee         300 300      
Maximum                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Property, plant and equipment, useful life     5 years            
Joint venture, quarterly promotion fee per prescription               $ 1,250  
Maximum | Forecast                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Joint venture, quarterly promotion fee per prescription         $ 1,000 $ 1,000      
Shipping and Handling                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Cost of revenue     $ 1,400 $ 1,400          
Revenue Benchmark | Supplier Concentration Risk                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Percent of total revenue     97.00% 97.00%          
Revenue Benchmark | AVISE CTD Test | Product Concentration Risk                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Percent of total revenue     70.00% 82.00%          
Janssen (SIMPONI)                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Revenue     $ 5,100 $ 1,500          
Other assets                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Restricted cash                 $ 100